Inovio Pharmaceuticals Inc vs Micron Technology, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Micron Technology, Inc. trades at $918.73 (market cap $980.90B). The key difference: Micron Technology, Inc. is far larger — about 12487.6× Inovio Pharmaceuticals Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | MU | |
|---|---|---|
Market Cap | $78.55M | $980.90B |
Sector | Health | Technology |
52-Week High | $2.87 | $1.21K |
52-Week Low | $0.66 | $115.79 |
Enterprise Value | $49.56M | $961.25B |
Dividend Yield | — | 0.06% |
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Micron Technology (MU) trades at $921.01, up 6.97% in 24 hours, with strong earnings beats in recent quarters and robust profitability metrics. Technical indicators show a bearish short-term signal, with the stock near resistance at $877. The company exhibits exceptional gross margins of 72.57% and net income margin of 55.91%, supported by surging memory demand and strategic customer agreements.
Outlook remains positive due to AI-driven memory demand and locked-in revenues, but risks include cyclical industry pressures and competitive threats. Analyst consensus is strongly bullish with an average price target of $1,540, suggesting significant upside potential from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →